SCHEMBL930048

SCHEMBL930048

CN1CCN(c2ccc(-n3c(=O)n(C)c4cnc5ccc(-c6cccnc6)cc5c43)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 9/20 0.62
PIK3CA P42336 7/20 0.62
PIK3CD O00329 7/20 0.62
PIK3CB P42338 6/20 0.62
PIK3CG P48736 6/20 0.62
ATM Q13315 5/20 0.61
ATR Q13535 3/20 0.61
KCNH2 Q12809 1/20 0.61
CLK4 Q9HAZ1 2/20 0.56
MEN1 O00255 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
ALOX15 P16050 1/20 0.56
MAPK1 P28482 1/20 0.56
KMT2A Q03164 1/20 0.56
PIK3C2A O00443 2/20 0.54
PIK3C2B O00750 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Maleic Acid SCHEMBL996441 0.93 MTOR (0.55) MTORPIK3CAPIK3CDPIK3CBPIK3CG
Fumaric Acid SCHEMBL996442 0.93 MTOR (0.55) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL9901524 0.91 PIK3CA (0.56) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL927267 0.89 MTOR (0.54) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL930080 0.89 ATM (0.53) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL930601 0.86 MTOR (0.65) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL12764675 0.86 MTOR (0.63) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL993850 0.85 MTOR (0.73) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL928744 0.85 MTOR (0.76) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL926905 0.85 MTOR (0.62) MTORPIK3CAPIK3CDPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2270008-B1 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors NOVARTIS AG (CH) 2012-10-03 EP claimed
US-7994170-B2 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2011-08-09 US claimed
EP-2292617-A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors Novartis AG (CH) 2011-03-09 EP claimed
EP-2270008-A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors Novartis AG (CH) 2011-01-05 EP claimed
US-20100056558-A1 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-04 US claimed
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors NOVARTIS AG (CH) 2008-08-14 US claimed
EP-1888578-A2 IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2008-02-20 EP claimed
WO-2006122806-A2 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2006-11-23 WO claimed
US-9370508-B2 Imidazoquinolines as dual lipid kinase and mTOR inhibitors NOVARTIS AG (CH) 2016-06-21 US disclosed
EP-2624831-A1 PHARMACEUTICAL COMBINATIONS Novartis AG (CH) 2013-08-14 EP disclosed
US-20130178479-A1 PHARMACEUTICAL COMBINATIONS NOVARTIS AG (CH) 2013-07-11 US disclosed
US-8431592-B2 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2013-04-30 US disclosed
US-20120282252-A1 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes NOVARTIS AG (CH) 2012-11-08 US disclosed
EP-2270008-B1 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors NOVARTIS AG (CH) 2012-10-03 EP disclosed
EP-2129379-A1 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS Novartis AG (CH) 2009-12-09 EP disclosed
WO-2009118324-A1 5IMIDAZOQUINOLINES AND PYRIMIDINE DERIVATIVES AS POTENT MODULATORS OF VEGF-DRIVEN ANGIOGENIC PROCESSES NOVARTIS AG (CH) 2009-10-01 WO disclosed
WO-2008103636-A1 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS NOVARTIS AG (CH) 2008-08-28 WO disclosed
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors NOVARTIS AG (CH) 2008-08-14 US disclosed
EP-1888578-A2 IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2008-02-20 EP disclosed
WO-2006122806-A2 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056558-A1 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS PDPK1, PI4KA, PIP4K2A MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885
US-20130178479-A1 PHARMACEUTICAL COMBINATIONS MTOR, RICTOR, PIK3CA MTOR 1/4885PIK3CA 3/4885PIK3CD 4/4885
US-20120282252-A1 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes KDR, FLT4, TEK MTOR 2286/4885PIK3CA 1091/4885PIK3CD 1413/4885
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors PDPK1, PI4KA, PIP4K2A MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.